Commentary
Podcast
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Author(s):
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
On this episode of Managed Care Cast, we're talking with Jason Shafrin, PhD, the senior managing director of FTI Consulting's Center for Healthcare Economics and Policy and an adjunct professor in the University of Southern California's Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences.
His study, "Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy," estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment from a survey of individuals planning to have children.
Listen above or on one of these podcast services:
Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
